Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Krystal Biotech, Inc.    KRYS

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Krystal Biotech, Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Company's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness and dehydration.

Number of employees : 51 people.
Managers
NameAgeSinceTitle
Krish S. Krishnan532015Chairman, President & Chief Executive Officer
Suma M. Krishnan532016Chief Operating Officer & Director
Dan S. Janney532016Independent Director
Dino A. Rossi642017Independent Director
Rockford Norby842017Lead Independent Director
Kirti Wardhaman Ganorkar-2017Independent Director
Julian S. Gangolli612019Independent Director
Pooja Agarwal-2016Vice President-Product Development
Bo Lin-2018Accounting Manager
Jennifer Chien-2020Chief Commercial Officer
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 17,357,935 11,760,451 67.8% 0 0.0% 67.8%
Shareholders
NameEquities%
Krish S. Krishnan 1,936,462 11.2%
Suma M. Krishnan 1,936,064 11.2%
Frazier Management LLC 1,790,000 10.3%
Fidelity Management & Research Co. 1,148,286 6.63%
Redmile Group LLC 1,090,200 6.30%
T. Rowe Price Associates, Inc. (Investment Management) 1,050,585 6.07%
Baker Bros. Advisors LP 1,034,674 5.98%
OrbiMed Advisors LLC 994,808 5.75%
Sun Pharmaceutical Industries Limited 914,107 5.28%
The Vanguard Group, Inc. 593,125 3.43%
Company contact information
Krystal Biotech, Inc.
2100 Wharton Street
Suite 701
Pittsburgh, PA 15203

Phone : +1.412.586.5830
Web : http://www.krystalbio.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
KRYSTAL BIOTECH, INC.-28.53%751
GILEAD SCIENCES18.47%94 124
VERTEX PHARMACEUTICALS10.60%61 693
REGENERON PHARMACEUTICALS32.83%53 154
WUXI APPTEC CO., LTD.1.90%21 017
GENMAB A/S-6.92%13 229
BEIGENE, LTD.-17.74%9 553
HUALAN BIOLOGICAL ENGINEERING INC.5.55%9 494
NEUROCRINE BIOSCIENCES, INC.-19.70%7 988
SAREPTA THERAPEUTICS, INC.-25.62%7 608
ARGENX SE-15.11%5 784
ASCENDIS PHARMA A/S-20.31%5 376
EXELIXIS, INC.-5.51%5 259
REATA PHARMACEUTICALS, INC.-33.78%4 796
ACCELERON PHARMA INC.57.68%4 793
FORTY SEVEN, INC.142.39%4 595
PEPTIDREAM INC.0.80%4 406
SPARK THERAPEUTICS, INC.0.00%4 375
BIOCON LIMITED-2.68%4 250
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.-12.18%4 153
ZAI LAB LIMITED23.80%3 813